Morinaga M-16V

Bifidobacterium is a well-studied genus of beneficial bacteria that naturally inhabits the human gut. There are many speciesof bifidobacteria, and, like all probiotics, their health benefits are strain-specific. Bifidobacterium breve is a species of bifidobacteria commonly found in the intestines of newborn infants. Morinaga M-16V is a room-temperature stable strain of Bifidobacterium breve supported by over 30 published studies, including 19 human clinical trials. It has special benefits for low-birth-weight infants. In fact, Morinaga M-16V is routinely administered to low-birth-weight infants in the Neonatal Intensive Care Units of approximately 100 hospitals in Japan.

Published scientific studies have shown that in children and/or babies, including low-birth-weight infants, Morinaga M-16V:

  • Restores Bifidobacterium to normal levels*[1],[2],[3]
  • Supports a healthy immune system*[4]
  • Promotes respiratory health*[5],[6]
  • Supports skin health*[7],[8]





    Morinaga M-16V may work through a number of ways to protect the health of children and infants, including:

    Supporting the health of the gastro-intestinal mucosal layer*[9],[10]

    Modulating the immune response through acting on T-helper cells, immunoglobulin E and galectin-9*[11],[12]


    Safety is of the utmost importance in products intended for medically fragile populations such as pre-term or low-birth-weight infants. Bacteria of the Bifidobacterium genus occur naturally in the human gut and are associated with good health. The safety of Morinaga M-16V has been confirmed by oral toxicity tests, analysis of antibiotic resistance, genomic analysis and numerous clinical studies, which found no adverse effects among study subjects.*[13],[14] Morinaga M-16V has been granted  FDA GRAS status in the United States for food applications and infant formulas.

    [1] Li Y, et al. Pediatr Int. 2004 Oct;46(5):509-15.

    [2] Akiyama K, et al. J Jpn Soc Premat Newborn Med. 1996 Mar;8(1):59-64.

    [3] Bennet R, Nord CE, Zetterström R. Acta Paedriat. 1992;81:784-7.

    [4] Ezaki S, et al. Allergol Int. 2012 Mar;61(1):107-13.

    [5] van der Aa LB, et al. Allergy. 2011 Feb;66(2):170-7.

    [6] van de Pol MA, et al. Allergy. 2011 Jan;66(1):39-47

    .[7] van der Aa LB, et al. Clin Exp Allergy. 2010 May;40(5):795-804.

    [8] Taniuchi S, et al. Journal of Applied Research. 2005;5(2):387-96.

    [9] Wang C, et al. J Ped Gastroenterol Nutr. 2007;44:252-7.

    [10] Fujii T, et al. J of Ped Gastroenterol. Nutr. 2006 Jul;43:83-88.

    [11] Schouten B, et al. J Nutr. 2009 Jul;139(7):1398-403.

    [12] de Kivit S, et al. Allergy. 2012 Mar;67(3):343-52.

    [13] Abe F, Yaeshima T, Iwatsuki K. Bioscience Microflora. 2009;28(1):7-15.

    [14] Abe F, et al. Anaerobe. 2010;16:131-16.